MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.82 CNY | -0.62% |
|
+3.52% | +19.19% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,785 | 7,539 | 8,681 | 12,397 | 9,742 | 10,423 |
| Enterprise Value (EV) 1 | 4,337 | 5,693 | 6,490 | 9,901 | 7,073 | 7,644 |
| P/E ratio | 32.7 x | 20.8 x | 20.8 x | 26.6 x | 20.4 x | 23.5 x |
| Yield | 1.12% | 1.49% | 1.49% | 1.22% | 1.55% | 1.65% |
| Capitalization / Revenue | 2.63 x | 2.79 x | 3.11 x | 3.66 x | 2.76 x | 3.32 x |
| EV / Revenue | 1.97 x | 2.1 x | 2.32 x | 2.92 x | 2 x | 2.44 x |
| EV / EBITDA | 12.8 x | 14.2 x | 17 x | 20.1 x | 13.2 x | 17.9 x |
| EV / FCF | 21.1 x | 17 x | 10.5 x | 35.2 x | 26.9 x | 58.9 x |
| FCF Yield | 4.75% | 5.88% | 9.48% | 2.84% | 3.72% | 1.7% |
| Price to Book | 2.55 x | 2.95 x | 3.05 x | 3.91 x | 2.79 x | 2.79 x |
| Nbr of stocks (in thousands) | 431,054 | 431,054 | 431,054 | 431,054 | 431,054 | 431,054 |
| Reference price 2 | 13.42 | 17.49 | 20.14 | 28.76 | 22.60 | 24.18 |
| Announcement Date | 4/27/19 | 4/24/20 | 3/25/21 | 3/22/22 | 4/7/23 | 4/12/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,198 | 2,705 | 2,792 | 3,385 | 3,532 | 3,137 |
| EBITDA 1 | 340.1 | 402.3 | 381.9 | 491.5 | 535.1 | 427.1 |
| EBIT 1 | 306.2 | 368.7 | 349.1 | 453.4 | 494.3 | 384.7 |
| Operating Margin | 13.93% | 13.63% | 12.5% | 13.39% | 13.99% | 12.27% |
| Earnings before Tax (EBT) 1 | 191.7 | 422.4 | 497.7 | 548.2 | 559.1 | 524.7 |
| Net income 1 | 176.2 | 360 | 419.1 | 464.6 | 479 | 443.3 |
| Net margin | 8.02% | 13.31% | 15.01% | 13.72% | 13.56% | 14.13% |
| EPS 2 | 0.4100 | 0.8400 | 0.9700 | 1.080 | 1.110 | 1.030 |
| Free Cash Flow 1 | 205.8 | 334.9 | 615.5 | 281.2 | 263.4 | 129.8 |
| FCF margin | 9.37% | 12.38% | 22.05% | 8.31% | 7.46% | 4.14% |
| FCF Conversion (EBITDA) | 60.52% | 83.24% | 161.14% | 57.22% | 49.21% | 30.39% |
| FCF Conversion (Net income) | 116.81% | 93.03% | 146.87% | 60.54% | 54.98% | 29.28% |
| Dividend per Share 2 | 0.1500 | 0.2600 | 0.3000 | 0.3500 | 0.3500 | 0.4000 |
| Announcement Date | 4/27/19 | 4/24/20 | 3/25/21 | 3/22/22 | 4/7/23 | 4/12/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,448 | 1,846 | 2,192 | 2,496 | 2,669 | 2,779 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 206 | 335 | 615 | 281 | 263 | 130 |
| ROE (net income / shareholders' equity) | 7.12% | 14.2% | 15.4% | 15.1% | 13.9% | 12.1% |
| ROA (Net income/ Total Assets) | 6.74% | 7.42% | 6.1% | 7.09% | 6.73% | 4.85% |
| Assets 1 | 2,615 | 4,852 | 6,868 | 6,553 | 7,121 | 9,141 |
| Book Value Per Share 2 | 5.270 | 5.930 | 6.610 | 7.360 | 8.110 | 8.670 |
| Cash Flow per Share 2 | 2.570 | 3.570 | 4.810 | 5.640 | 5.780 | 6.930 |
| Capex 1 | 25 | 46.4 | 45.4 | 65.1 | 75 | 248 |
| Capex / Sales | 1.14% | 1.71% | 1.63% | 1.92% | 2.12% | 7.92% |
| Announcement Date | 4/27/19 | 4/24/20 | 3/25/21 | 3/22/22 | 4/7/23 | 4/12/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +19.19% | 1.73B | |
| +20.83% | 43.57B | |
| +20.70% | 22.7B | |
| +16.41% | 14.32B | |
| +11.11% | 13.42B | |
| +45.91% | 11.83B | |
| -8.84% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.51B |
- Stock Market
- Equities
- 600993 Stock
- Financials Mayinglong Pharmaceutical Group Co., LTD.